Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NI-2801
- Development stage
- Preclinical
- Lead developer
- Lightchain Bioscience
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
NI-2801 is a bispecific antibody targeting CD47 and HER2, developed by Lightchain Bioscience using its proprietary κλ body platform. It is designed to treat HER2-positive solid tumors by selectively blocking the 'don't eat me' signal (CD47) on tumor cells that overexpress HER2. The molecule features a high-affinity HER2-targeting arm and an optimized low-affinity CD47-binding arm, which minimizes off-target binding to CD47 on healthy cells like red blood cells and platelets. NI-2801 incorporates a fully competent IgG1 Fc-domain to facilitate antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). It is currently in the preclinical stage of development.
- Other names
- NI-2801-Lightchain-CD47-HER2-bispecific antibodyNI2801-Lightchain-CD47-HER2-bispecific antibodyNI 2801-Lightchain-CD47-HER2-bispecific antibody
02
Targets
CD47 (Cluster of Differentiation 47)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on NI-2801.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NI-2801.